Earnings Preview – ABT, BAX, BDX
Our Strategies work regardless of market direction or economic conditions
NOTE TO READERReal Time Trading Reports:
Included here are detailed trading reports designed to help investors realize opportunities in these companies. The reports are immediately actionable.
Find Links Below:
Performance - Click Here.
(La Jolla, CA) This is a busy week for healthcare, as companies in various subsectors from Pharma to Medical Devices are set to report 4Q earnings results. Here we take a look at three of the top players scheduled to announce profits during the second half of the week – Abbott Laboratories, Baxter, and Becton Dickinson.
Abbott (NYSE: ABT) will be the first of the group to announce results. The company is expected to report earnings per share of $1.17 and revenues $8.6 billion on Wednesday. Wall Street analysts believe that profits will be driven by strong pharma sales. Despite weak domestic results due to the economy and competition from generic drug makers, Abbott is getting a strong boost from international sales stemming from a decreasing dollar. Investors in 2010 will be eager to find out the impact of Abbott’s recent acquisitions across a wide range of sectors, including Solvay, Starlims Technologies, and Advanced Medical Optics. The company expects these acquisitions as well as plans to build its Diagnostic and Nutrition segments will be key growth factors. To read about additional investment considerations for Abbott, take a look at our free ABT trading report. Shares of Abbott closed at $54.70 on Monday.
Baxter (NYSE: BAX), scheduled to report earnings Thursday, is expected to earn $1.03 per share and $3.4 billion in revenues. Biosciences should lead the other segments in sales (double digit growth), however like Abbott all divisions are benefiting from strong international results due to the weakening dollar. Revenues from the H1N1 vaccine should provide approximately $30 million in sales according to Wall Street analysts. However, as swine flu fears and cases decrease, it is uncertain how long that demand will last. Shares of Baxter closed $58.96 Monday, which is at the higher end of its 52 week range. To read more about Baxter’s strategic goals for 2010 and whether expected product launches will boost its stock price, download our free BAX trading report.
Becton Dickinson (NYSE: BDX) is also scheduled to announce earnings Thursday. The company is expected to report Q1 2010 profits of $1.20 per share and $1.8 billion in revenues. With a large portfolio of medical devices, the company has suffered a drop in sales due to the struggling economy. Major customers cut spending dramatically for new equipment purchases. Fortunately for BD, that loss is offset by increased demand for H1N1 vaccine this quarter. As for Baxter, that demand could soon taper off, but BD is already planning new product launches for Diabetes and is scheduled to open a new bio-processing facility in Miami. These initiatives, along with potential stimulus funding, could stabilize near term drops in sales and prepare the company for long term growth. Shares of BD closed $75.78 Monday, compared to its 52 week high of $79.97. To learn more about BD and if it is the right time to invest, read our free BDX trading report.
Special Reports:
- 2010 - The Year of the Increase - A precursor to market action in 2010
- Sell Gold - Expect Dollar Stability - This was issued on December 2, 2009.
- Top of the Market to you - Round 2 - Proves the next major top.
- S&P historical Valuation Comparisons - Compares today's market to past environments.
- The Treasury Bubble is bursting - The case for higher interest rates.
Sign up for a free Trial to read each one.
Membership Options - select one
- 10 Day Free Trial
- Access to our forecasting models
- $299 per month afterwards
- Access to our educational webinars
- Upgrade to Platinum at any time
- Access to our Market Analysis
- No cost if cancelled within 10 Days
- Review our performance records
- Access to our stock reports
- Access to The Investment Rate
- Access to Trend Tracker
- Access to our proactive strategies
- Access to our Economic analysis
- Support: chat, email, and phone
10 Day Free Trial Offer
(you can cancel at any time)Here are a few of the services we offer. Sign up for a Free Trial to find out more.
Buy and Hold is Dead
- No time to control risk?
- Lacking the discipline to do it right?
- Trend Tracker is the solution.
Trend Tracker allows everyone to control risk and realize opportunities regardless of market direction or economic conditions, and without sacrificing time or lifestyle. Work, play golf, or trade other stocks and feel confident that your wealth is protected, and you are positioning yourself to make money.
Anyone, even people with normal jobs, can use Trend Tracker to bring the paradigm of risk control to their investment decisions from this point forward. From now on, your efforts will be easy, efficient, and results - driven.
Sign up for a free trial to learn more.
Empower your competitive Advantage:
Buy and Hold is Dead! You must assume the responsibility of risk control for yourself, and become a Proactive Investor. Money managers are more concerned with generating fees, they are paid to invest money, they do not control risk. Everyone realized that again in 2008. It is a repetitive lesson that some investors will never learn.
Diversification is a great approach when the market is increasing, but that strategy has not worked since 2000, and it is not likely to start working again anytime soon. The Investment Rate proves it. Know what is says.
Stop being at the mercy of the Market, and empower your competitive advantages today. We will teach you how to do it effectively and efficiently so you will never be at the mercy of the Market again.
Thomas H. Kee Jr., President
The Investment Rate is the most accurate leading longer term stock market and economic indicator ever developed. It is the foundation of everything we do. The IR measures the rate of change in the amount of new money available for investment into our economy every year, and for extended periods of time. If has predicted the Great Depression, the Stagflation Period of the 1970s, and the up-periods in between. It impacts all asset classes: stocks, real estate, private business, and any other asset class that relies on new money to grow. Use it to make investment decisions and business decisions. The accuracy is unparalleled. Find out what it says about the immediate future by signing up for a free trial, and see if your decisions line up with the most accurate leading economic indicator in history.
Most money managers do not control risk. They get paid to invest money, not to move it to cash. You must control your own risk; you have to. This is not an option. However, it does not have to be complicated either. Our services are designed to make the transition to risk control seamless. We all know we should do it, now anyone can do it. All of our strategies are focused on risk control and wealth preservation. Performance is a natural byproduct. Stop chasing performance, and start chasing risk control. You will be happier, and better off. Sign up for a free trial to see how our services can make risk control and opportunity paradigm for you too.
A revolution in rule based trading. Trend Tracker is an automated - correlated market timing and stock selection tool that allows normal people, with normal jobs, to control their risk and realize opportunities regardless of economic conditions or market direction, and without sacrificing time or lifestyle. Work, play golf, or trade other stocks, and feel confident that your wealth is being protected and that you are positioning yourself to profit when opportunities arise.
Sign up for a free trial to learn more.
We offer trading reports on 1300 different companies through Reuters.